Specialty drug and medical device maker Baxter International Inc. said it will spend up to $330 million to acquire ApaTech, a privately held British concern that makes bone and soft tissue replacement material using biochemistry.
Baxter said it will pay $240 million cash for the orthobiologic products company and then pay up to $90 million more when sales milestones are reached. The deal is expected to close in the first quarter.
The acquisition will give Baxter a bone graft material called Actifuse marketed in the United States and Europe. The Deerfield, Ill., company also will acquire U.S., British and German manufacturing and research sites.
Baxter called ApaTech's product pipeline "highly complementary to our existing commercial and technical capabilities in biosurgery."
Latest from Today's Medical Developments
- NextDent 300 MultiJet printer delivers a “Coming of Age for Digital Dentistry” at Evolution Dental Solutions
- Get recognized for bringing manufacturing back to North America
- Adaptive Coolant Flow improves energy efficiency
- VOLTAS opens coworking space for medical device manufacturers
- MEMS accelerometer for medical implants, wearables
- The compact, complex capabilities of photochemical etching
- Moticont introduces compact, linear voice coil motor
- Manufacturing technology orders reach record high in December 2025
